<DOC>
	<DOCNO>NCT00031681</DOCNO>
	<brief_summary>This phase I trial study side effect best dose give 7-hydroxystaurosporine together irinotecan hydrochloride treat patient metastatic unresectable solid tumor , include triple-negative breast cancer ( currently enrol patient triple-negative breast cancer since 6/8/2007 ) . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving 7-hydroxystaurosporine together irinotecan hydrochloride may help kill cancer cell make tumor cell sensitive drug .</brief_summary>
	<brief_title>7-Hydroxystaurosporine Irinotecan Hydrochloride Treating Patients With Metastatic Unresectable Solid Tumors Triple Negative Breast Cancer ( Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007 )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose UCN-01 ( 7-hydroxystaurosporine ) irinotecan ( irinotecan hydrochloride ) patient resistant solid tumor . ( Part I [ close accrual 6/8/2007 ] ) II . Determine dose-limiting toxicity regimen patient . ( Part I [ close accrual 6/8/2007 ] ) III . Determine type toxic effect regimen patient . ( Part I [ close accrual 6/8/2007 ] ) IV . Determine anti-tumor activity term overall response rate ( partial response [ PR ] complete response [ CR ] ) , clinical benefit rate ( PR , CR , stable disease ) , time disease progression patient estrogen receptor-negative , progesterone receptor-negative , HER-2 amplify ( triple negative ) locally recurrent metastatic breast cancer treat regimen . ( Part II ) V. Determine side effect profile regimen patient triple negative recurrent breast cancer . ( Part II ) SECONDARY OBJECTIVES : I . Determine anti-tumor activity regimen patient . ( Part I [ close accrual 6/8/2007 ] ) II . Determine pharmacokinetics regimen patient . ( Part I [ close accrual 6/8/2007 ] ) III . Determine activity serum α-acid glycoprotein correlate level free UCN-01 concentration . ( Part I [ close accrual 6/8/2007 ] ) IV . Determine vivo mechanism UCN-01 activity patient . OUTLINE : This dose-escalation study . PART I : Patients receive irinotecan hydrochloride intravenously ( IV ) 90 minute day 1 , 8 , 15 , 22 7-hydroxystaurosporine IV 3 hour day 2 23 . Courses repeat every 42 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan hydrochloride 7-hydroxystaurosporine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Blood sample collect periodically study treatment . PART II : ( treatment triple negative recurrent breast cancer ) : Patients receive irinotecan hydrochloride IV 7-hydroxystaurosporine IV part I MTD undergo blood sample collection .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Paranasal Sinus Neoplasms</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Carcinoma , Mucoepidermoid</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Esthesioneuroblastoma , Olfactory</mesh_term>
	<mesh_term>Papilloma , Inverted</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Part I ( close accrual 6/8/2007 ) Histologically confirm solid tumor metastatic unresectable standard curative measure exist longer effective , include follow : Gastrointestinal tract cancer Lung cancer Breast cancer Ovarian cancer Endometrial cancer Cervical cancer Prostate cancer Head neck cancer Patients without measurable evaluable disease allow Measurable disease , define ≥ 1 unidimensionally measurable lesion &gt; 20 mm conventional technique ≥ 10 mm spiral CT scan Tumor marker allow evaluable disease Positive bone scan , osteoblastic metastasis , pleural peritoneal effusion consider measurable evaluable disease No known brain metastasis Part II Histologically confirm ( either primary recurrent site ) locally recurrent metastatic breast cancer amendable surgery Measurable disease For skin lesion , documentation color photography estimation lesion size ruler require Must undergone prior therapy anthracycline taxane either adjuvant metastatic setting CNS metastasis allow provide stable disease ( i.e. , evidence local progression ) ≥ 3 month local therapy Hormone receptor status : Estrogen receptor negative Progesterone receptor negative HER2 amplify fluorescence situ hybridization Performance status ECOG 02 Performance status Karnofsky 60100 % More 12 week WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin ≥ 10 g/dL Bilirubin normal AST/ALT great 3 time upper limit normal ( ULN ) No Gilbert 's disease No chronic unconjugated hyperbilirubinemia Creatinine great 1.5 time ULN Creatinine clearance least 60 mL/min No symptomatic cardiac dysfunction No symptomatic pulmonary dysfunction Oxygen saturation least 90 % pulse oximetry room air rest walk 6 minute No insulindependent diabetes mellitus No uncontrolled concurrent illness No active ongoing infection No psychiatric illness social situation would preclude study entry No prior allergic reaction attribute compound similar chemical biological composition UCN01 irinotecan Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent granulocyte colonystimulating factor ( filgrastim [ GCSF ] sargramostim [ GMCSF ] ) first course study See Disease Characteristics ( Part II ) More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior irinotecan allow Less 4 prior chemotherapy regimen adjuvant and/or metastatic setting ( Part II ) More 4 week since prior radiotherapy recover Concurrent warfarin allow Concurrent subcutaneous heparin allow No concurrent investigational agent No concurrent anticonvulsant ( e.g. , carbamazepine , phenobarbital , phenytoin ) No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>